Patients showing tumor response or stable disease with chemotherapy did better when switched to molecularly targeted treatments than those who continued chemotherapy.
Cancer of unknown primary (CUP) has been associated with a poor prognosis, short survival, and treatment approaches that typically utilize generic chemotherapy regimens with antitumor activity in the most likely primary sites of disease. These regimens often are platinum- or taxane-based combinations associated with little improvement in overall survival (OS). To determine the effect of a molecularly guided treatment (MGT) of CUP, researchers conducted an industry-sponsored, multinational, phase 2, open-label trial.
They enrolled 636 patients with nonsquamous CUP and good functional status who were eligible for platinum-based chemotherapy and had tumor tissue or liquid biopsy material available for gene expression profiling. Patients first r…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)